Get the Stockscreener App
461.24
0.48%
-2.24
After Hours:
462.00
0.76
+0.16%
Vertex Pharmaceuticals Inc stock is traded at $461.24, with a volume of 1.85M.
It is down -0.48% in the last 24 hours and down -0.56% over the past month.
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
See More
Previous Close:
$463.48
Open:
$460.43
24h Volume:
1.85M
Relative Volume:
1.31
Market Cap:
$117.03B
Revenue:
$11.74B
Net Income/Loss:
$3.68B
P/E Ratio:
32.51
EPS:
14.1888
Net Cash Flow:
$3.34B
1W Performance:
-1.97%
1M Performance:
-0.56%
6M Performance:
+23.17%
1Y Performance:
+1.32%
1-Day Range:
$454.40
$464.73
1-Week Range:
$454.40
$478.54
52-Week Range:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals Inc
Sector
Industry
Phone
(617) 341-6393
Address
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
461.24 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
778.97 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
834.55 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.28 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
351.27 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-22-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-12-26 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jan-07-26 | Resumed | UBS | Buy |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-03-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-25-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-03-25 | Initiated | Raymond James | Mkt Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-07-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Feb-11-25 | Upgrade | Canaccord Genuity | Sell → Hold |
| Jan-30-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Perform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-05-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-27-24 | Initiated | Redburn Atlantic | Buy |
| Apr-11-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
| Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
| May-30-23 | Initiated | William Blair | Outperform |
| May-04-23 | Resumed | Piper Sandler | Overweight |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-27-22 | Reiterated | JP Morgan | Overweight |
| Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
| Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-27-22 | Reiterated | Stifel | Hold |
| Jan-27-22 | Reiterated | Wolfe Research | Outperform |
| Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-09-21 | Downgrade | Stifel | Buy → Hold |
| Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jul-01-21 | Initiated | Raymond James | Mkt Perform |
| Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-30-20 | Initiated | Daiwa Securities | Outperform |
| Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-20-20 | Initiated | Bernstein | Outperform |
| Oct-28-20 | Initiated | UBS | Buy |
| Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
| Aug-01-19 | Downgrade | Needham | Buy → Hold |
| May-23-19 | Resumed | Citigroup | Buy |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | In-line |
| Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals Inc Stock (VRTX) Latest News
Vertex Pharmaceuticals (VRTX) Q4 Earnings Preview: Key Expectati - GuruFocus
Biotech Stocks To Add to Your WatchlistFebruary 11th - MarketBeat
Vertex Pharmaceuticals's Earnings Outlook - Benzinga
Wealthfront Advisers LLC Trims Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Caprock Group LLC Acquires Shares of 25,216 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect - Finviz
Vertex Pharmaceuticals (VRTX) Receives FDA Orphan Drug Status fo - GuruFocus
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell - Yahoo Finance
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell - The Motley Fool
Vertex Pharmaceuticals at Turning Point Ahead of Phase 3 Kidney Drug Data, RBC Says - marketscreener.com
Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards? - TradingView
Should You Buy Vertex Before Feb. 12? - Nasdaq
Oppenheimer Asset Management Inc. Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
A Look At Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Momentum - Yahoo Finance
How Investors Are Reacting To Vertex (VRTX) Expanding Into Trispecific T-Cell Engagers For Autoimmune Diseases - Yahoo Finance UK
2 Top Healthcare Stocks to Buy in February - AOL.com
Should You Buy Vertex Pharmaceuticals Before Feb. 12? - The Globe and Mail
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - The Globe and Mail
Vertex Q4 Earnings Preview: What To Expect This Week (NASDAQ:VRTX) - Seeking Alpha
Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by ProShare Advisors LLC - MarketBeat
Stocks Generating Improved Relative Strength: Vertex Pharmaceuticals - Investor's Business Daily
BI Asset Management Fondsmaeglerselskab A S Sells 3,075 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Autoimmune Pipeline Expansion With WuXi Biologics - simplywall.st
Hantz Financial Services Inc. Purchases 4,864 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Envestnet Asset Management Inc. Has $184.37 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Five things for pharma marketers to know for Friday, February 6, 2026 - Medical Marketing and Media
Best Biotech Stocks of 2026 and How to Invest in Them - The Motley Fool
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Finviz
Does WuXi Trispecific T-cell Engager Deal Reshape the Bull Case for Vertex Pharmaceuticals (VRTX)? - simplywall.st
Vertex’s CRISPR treatment for sickle cell disease hits unexpected roadblock - statnews.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by AGF Management Ltd. - MarketBeat
ABN AMRO Bank N.V. Increases Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals (VRTX) Pricing Reflect Long Term Cash Flow Potential After Recent Pullback - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Vertex Pharmaceuticals (VRTX) Projected to Post Earnings on Thursday - MarketBeat
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug - MSN
The Truth About Vertex Pharma: Why Wall Street Suddenly Can’t Shut Up - AD HOC NEWS
Callan Family Office LLC Has $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Machina Capital S.A.S. Acquires Shares of 11,167 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Brookdale Senior Living (BKD) - The Globe and Mail
Rep. David Taylor Sells Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock - MarketBeat
WUXI BIO, Vertex Pharmaceuticals Sign License & Research Service Agreement for T-cell Engager - AASTOCKS.com
Biopharma bites: Updated data for Ultragenyx's gene therapy, AI newco's $13.5M seed round, plus more from NMD, Vertex - FirstWord Pharma
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? - Yahoo Finance
Here's How Much a $1000 Investment in Vertex Pharmaceuticals Made 10 Years Ago Would Be Worth Today - Yahoo Finance
WuXi licenses trispecific immune engager to Vertex - The Pharma Letter
Vertex (VRTX) Secures Exclusive Rights for Innovative Autoimmune Treatment - GuruFocus
Thrivent Financial for Lutherans Sells 9,932 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Atlantic Union Bankshares Corp Purchases 5,741 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by WCM Investment Management LLC - MarketBeat
Vertex Pharmaceuticals Inc Stock (VRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.19%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):